Summary of Absci (ABSI) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Research and Development Expenses: $22.6 million for Q2 2026, up from $20.5 million in Q2 2025, primarily due to advancing internal programs.

Selling, General and Administrative Expenses: $9.2 million for Q2 2026, compared to $8.5 million in the prior year, driven by stock-based compensation and administrative costs.

Cash Position: Cash, cash equivalents, and marketable securities totaled $201.1 million as of June 30, 2026, up from $125.7 million at the end of Q1 2026, bolstered by a $100 million financing round completed in June, including a $40 million investment from Eli Lilly.

Projected Cash Runway: Sufficient to fund operations into the second half of 2028.

2Strategic Updates and Business Highlights

Clinical Progress: Positive interim Phase I data for ABS-201, indicating favorable safety and tolerability, with a half-life suggesting potential for just 2-3 injections over six months.

Partnership with Eli Lilly: Strategic investment and collaboration focused on the clinical development of ABS-201, with a representative from Lilly joining the endometriosis advisory board.

Platform Development: Introduction of "Atlas," an AI-driven discovery engine aimed at enhancing target identification and drug design efficiency, which is expected to accelerate the development of new therapeutics.

3Forward Guidance and Outlook

Upcoming Milestones: Anticipated interim proof of concept (POC) data for ABS-201 in pattern hair loss later in 2026, with full POC data expected in early 2027. A Phase II clinical trial for ABS-201 in endometriosis is expected to initiate in Q4 2026.

Market Potential: Estimated total addressable market (TAM) for ABS-201 in pattern hair loss exceeds $25 billion in the U.S., with additional significant opportunities in endometriosis projected at over $4 billion.

4Bad News, Challenges, or Points of Concern

Market Competition: The competitive landscape for hair loss treatments remains challenging, with existing therapies showing varying degrees of effectiveness, which could impact the market entry of ABS-201.

Regulatory Risks: The success of ABS-201 is contingent on meeting regulatory requirements and achieving clinical endpoints, which carry inherent risks.

Consumer Understanding: The transition from "androgenetic alopecia" to "pattern hair loss" may require additional consumer education to ensure market acceptance.

5Notable Q&A Insights

Indication Definition: The shift from "androgenetic alopecia" to "pattern hair loss" was made to better reflect the underlying biology and consumer understanding.

Data Expectations: For the upcoming interim data, key metrics will include total area hair count, hair width, and safety data, while durability of effect will be assessed in follow-up studies beyond the initial 13 and 26 weeks.

Partnership Strategy: Absci aims to commercialize ABS-201 independently while maintaining the flexibility to partner on future programs based on strategic and financial considerations.

Durability of Response: The durability of hair regrowth from ABS-201 will not be fully understood until post-trial follow-up, highlighting the importance of sustained receptor occupancy for efficacy. This summary encapsulates the key points from Absci's Q2 2026 earnings call, providing a balanced view of the company's financial health, strategic direction, and potential challenges ahead.